Viridicatumtoxin B

Viridicatumtoxin B is a fungus-derived tetracycline antibiotic discovered in 2008. It was isolated from small amounts of penicillium fungi. A synthetic structure matching that of natural viridicatumtoxin B makes possible synthetic variants that match or surpass its antibiotic potency.[1]

Analogs lacking a hydroxyl group were even more effective than the original against Gram-positive bacteria.[1]

Concerns about solubility, biodegradation, availability and other issues must be resolved before clinical development begins.[1]

History

The substance was first isolated from the mycelium of liquid fermentation cultures of Penicillium species FR11.[2]

Structure

Its structure was determined on the basis of MS and nuclear magnetic resonance data.[2]

Effects

Viridicatumtoxin B inhibited the growth of Staphylococcus aureus, including methicillin resistant Staphylococcus aureus and quinolone-resistant S. aureus with MIC (μg/ml) of 0.5. That effect is similar to that of vancomycin, but 8-64 times greater than that of tetracycline.[2]

Total synthesis

A complete total synthesis of viridicatumtoxin B, in racemic form, was completed in 2013 by the group of K. C. Nicolaou.[3][4]

References

  1. 1 2 3 "Synthesis produces new antibiotic". Research & Development. Retrieved 2015-10-09.
  2. 1 2 3 Zheng, C. J.; Yu, H. E.; Kim, E. H.; Kim, W. G. (2008). "Viridicatumtoxin B, a new anti-MRSA agent from Penicillium sp. FR11". The Journal of Antibiotics. 61 (10): 633. doi:10.1038/ja.2008.84. PMID 19168978.
  3. ↑ http://onlinelibrary.wiley.com/doi/10.1002/anie.201304691/abstract
  4. ↑ http://pubs.acs.org/doi/abs/10.1021/ja506472u


This article is issued from Wikipedia - version of the 1/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.